Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi - Delavirdine - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:24 Organic chemistry Medicine Amides Merck Oxadiazoles Raltegravir Integrase Dolutegravir ViiV Healthcare Integrase inhibitors Chemistry Organofluorides		Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 46,87 KB Share Document on Facebook

	Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav DocID: 1ai1w - View Document
	Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S DocID: 1a5kT - View Document
	Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I DocID: 1a178 - View Document
	Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside DocID: 19KNn - View Document
	ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P DocID: 19FAE - View Document